GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004578527 | Esophagus | ESCC | positive regulation of cell adhesion | 255/8552 | 437/18723 | 5.07e-08 | 9.11e-07 | 255 |
GO:002240720 | Esophagus | ESCC | regulation of cell-cell adhesion | 239/8552 | 448/18723 | 5.88e-04 | 3.19e-03 | 239 |
GO:004211018 | Esophagus | ESCC | T cell activation | 256/8552 | 487/18723 | 1.18e-03 | 5.87e-03 | 256 |
GO:002240919 | Esophagus | ESCC | positive regulation of cell-cell adhesion | 155/8552 | 284/18723 | 1.50e-03 | 7.06e-03 | 155 |
GO:00508528 | Esophagus | ESCC | T cell receptor signaling pathway | 73/8552 | 123/18723 | 1.54e-03 | 7.24e-03 | 73 |
GO:000181916 | Esophagus | ESCC | positive regulation of cytokine production | 244/8552 | 467/18723 | 2.29e-03 | 1.01e-02 | 244 |
GO:005087015 | Esophagus | ESCC | positive regulation of T cell activation | 117/8552 | 216/18723 | 7.23e-03 | 2.62e-02 | 117 |
GO:190303916 | Esophagus | ESCC | positive regulation of leukocyte cell-cell adhesion | 128/8552 | 239/18723 | 8.40e-03 | 2.96e-02 | 128 |
GO:000715918 | Esophagus | ESCC | leukocyte cell-cell adhesion | 192/8552 | 371/18723 | 1.03e-02 | 3.51e-02 | 192 |
GO:190303717 | Esophagus | ESCC | regulation of leukocyte cell-cell adhesion | 174/8552 | 336/18723 | 1.36e-02 | 4.43e-02 | 174 |
GO:004578512 | Liver | HCC | positive regulation of cell adhesion | 215/7958 | 437/18723 | 2.53e-03 | 1.22e-02 | 215 |
GO:200011620 | Oral cavity | OSCC | regulation of cysteine-type endopeptidase activity | 152/7305 | 235/18723 | 1.14e-15 | 8.13e-14 | 152 |
GO:004328120 | Oral cavity | OSCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 137/7305 | 209/18723 | 5.94e-15 | 3.80e-13 | 137 |
GO:009719120 | Oral cavity | OSCC | extrinsic apoptotic signaling pathway | 142/7305 | 219/18723 | 7.34e-15 | 4.55e-13 | 142 |
GO:005254720 | Oral cavity | OSCC | regulation of peptidase activity | 255/7305 | 461/18723 | 5.78e-13 | 2.75e-11 | 255 |
GO:200011718 | Oral cavity | OSCC | negative regulation of cysteine-type endopeptidase activity | 64/7305 | 86/18723 | 2.53e-11 | 8.44e-10 | 64 |
GO:005254820 | Oral cavity | OSCC | regulation of endopeptidase activity | 235/7305 | 432/18723 | 4.35e-11 | 1.40e-09 | 235 |
GO:004315417 | Oral cavity | OSCC | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 59/7305 | 78/18723 | 4.86e-11 | 1.53e-09 | 59 |
GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CD27 | SNV | Missense_Mutation | rs748647585 | c.200N>T | p.Pro67Leu | p.P67L | P26842 | protein_coding | tolerated(0.07) | benign(0.028) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD27 | SNV | Missense_Mutation | | c.572N>A | p.Arg191His | p.R191H | P26842 | protein_coding | tolerated(0.23) | possibly_damaging(0.888) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
CD27 | SNV | Missense_Mutation | novel | c.189T>G | p.Asp63Glu | p.D63E | P26842 | protein_coding | tolerated(0.48) | benign(0) | TCGA-AP-A1DP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | PD |
CD27 | SNV | Missense_Mutation | rs71584831 | c.380C>T | p.Ser127Leu | p.S127L | P26842 | protein_coding | tolerated(0.4) | benign(0) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD27 | SNV | Missense_Mutation | | c.394T>C | p.Ser132Pro | p.S132P | P26842 | protein_coding | tolerated(1) | benign(0) | TCGA-AX-A063-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CD27 | SNV | Missense_Mutation | novel | c.165N>T | p.Gln55His | p.Q55H | P26842 | protein_coding | tolerated(0.11) | possibly_damaging(0.69) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
CD27 | SNV | Missense_Mutation | novel | c.647N>G | p.Lys216Arg | p.K216R | P26842 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CD27 | SNV | Missense_Mutation | | c.572N>A | p.Arg191His | p.R191H | P26842 | protein_coding | tolerated(0.23) | possibly_damaging(0.888) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
CD27 | insertion | Nonsense_Mutation | novel | c.503_504insTGACGGGCACCTGTAATCCCAGCTACTTGGGAG | p.Gln168delinsHisAspGlyHisLeuTerSerGlnLeuLeuGlyArg | p.Q168delinsHDGHL*SQLLGR | P26842 | protein_coding | | | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
CD27 | SNV | Missense_Mutation | novel | c.89N>A | p.Arg30Lys | p.R30K | P26842 | protein_coding | tolerated(1) | benign(0.005) | TCGA-CN-5373-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
939 | CD27 | PROTEASE INHIBITOR, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | 178101772 | | |
939 | CD27 | PROTEASE INHIBITOR, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | N/A | | |
939 | CD27 | PROTEASE INHIBITOR, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | CDX-1127 | VARLILUMAB | |
939 | CD27 | PROTEASE INHIBITOR, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | PROTEASE INHIBITORS | | 17309824 |
939 | CD27 | PROTEASE INHIBITOR, EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | | Varlilumab | VARLILUMAB | |